PIA
RCUS icon

Piedmont Investment Advisors’s Arcus Biosciences RCUS Stock Holding History

Piedmont Investment Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-90
Closed -$1K – 1993
2018
Q2 		$1K Buy
+90
New +$1.41K ﹤0.01% 2795

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Piedmont Investment Advisors's RCUS Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Arcus Biosciences (RCUS) in Q3 2018, closing a stake of 90 shares — an estimated $1K sold.

Piedmont Investment Advisors first reported a position in RCUS in Q2 2018 and held it in 1 quarter. The position peaked at $1K in Q2 2018. 57 funds tracked by Wall St. Rank hold RCUS as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Arcus Biosciences position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 90 Arcus Biosciences shares in Q3 2018, an estimated $1K.
  • Piedmont Investment Advisors first reported a position in Arcus Biosciences in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Arcus Biosciences position peaked at $1K in Q2 2018.
  • 57 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.